Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
75 inter-disciplinary, multi-institutional grants would be supported for high-risk, ambitious research ideas, milestones-driven collaborative research in all domain areas of the biotech sector
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
It plans to deliver over 300 million doses to the Indian government
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Subscribe To Our Newsletter & Stay Updated
